ABT-263
ABT-263
To Order Contact us: caitlyn@ucb-bioproducts.com
) ABT-263 (Navitoclax) |
|||
| A3007-100 | ApexBio | 100 mg | EUR 456 |
|
Description: ABT-263 is an orally sellecitive inhibitor of B-cell leukemia 2 (Bcl-2) family of proteins with potential antineoplastic activity. ABT-263 is a small molecular with the formula of C47H55ClF3N5O6S3 and Molecular Weight of 974. |
|||
ABT-263 (Navitoclax) |
|||
| A3007-1000 | ApexBio | 1 g | EUR 3298 |
|
Description: ABT-263 is an orally sellecitive inhibitor of B-cell leukemia 2 (Bcl-2) family of proteins with potential antineoplastic activity. ABT-263 is a small molecular with the formula of C47H55ClF3N5O6S3 and Molecular Weight of 974. |
|||
ABT-263 (Navitoclax) |
|||
| A3007-5 | ApexBio | 5 mg | EUR 108 |
|
Description: ABT-263 is an orally sellecitive inhibitor of B-cell leukemia 2 (Bcl-2) family of proteins with potential antineoplastic activity. ABT-263 is a small molecular with the formula of C47H55ClF3N5O6S3 and Molecular Weight of 974. |
|||
ABT-263 (Navitoclax) |
|||
| A3007-5.1 | ApexBio | 10 mM (in 1mL DMSO) | EUR 166 |
|
Description: ABT-263 is an orally sellecitive inhibitor of B-cell leukemia 2 (Bcl-2) family of proteins with potential antineoplastic activity. ABT-263 is a small molecular with the formula of C47H55ClF3N5O6S3 and Molecular Weight of 974. |
|||
ABT-263 (Navitoclax) |
|||
| A3007-50 | ApexBio | 50 mg | EUR 282 |
|
Description: ABT-263 is an orally sellecitive inhibitor of B-cell leukemia 2 (Bcl-2) family of proteins with potential antineoplastic activity. ABT-263 is a small molecular with the formula of C47H55ClF3N5O6S3 and Molecular Weight of 974. |
|||
ABT-263 (Navitoclax) |
|||
| A3007-S | ApexBio | Evaluation Sample | EUR 81 |
|
Description: ABT-263 is an orally sellecitive inhibitor of B-cell leukemia 2 (Bcl-2) family of proteins with potential antineoplastic activity. ABT-263 is a small molecular with the formula of C47H55ClF3N5O6S3 and Molecular Weight of 974. |
|||
 ABT |
|||
| B7737-5.1 | ApexBio | 10 mM (in 1mL DMSO) | EUR 108 |
ABT |
|||
| B7737-50 | ApexBio | 50 mg | EUR 125 |
 ABT-737 |
|||
| 2463-25 | Biovision | EUR 675 | |
ABT-737 |
|||
| 2463-5 | Biovision | EUR 207 | |
 ABT-869 |
|||
| 1615-1 | Biovision | EUR 213 | |
ABT-869 |
|||
| 1615-5 | Biovision | EUR 615 | |
 ABT-888 |
|||
| 1620-1 | Biovision | EUR 218 | |
ABT-888 |
|||
| 1620-5 | Biovision | EUR 615 | |
 ABT-494 |
|||
| B1947-25 | Biovision | EUR 892 | |
ABT-494 |
|||
| B1947-5 | Biovision | EUR 262 | |
 Abt-199 |
|||
| abx184638-1g | Abbexa | 1 g | EUR 648 |
|
|||
 Abt-869 |
|||
| 20-abx182361 | Abbexa |
|
|
|
|||
ABT-737 |
|||
| E1KS1002 | EnoGene | 5mg | EUR 521 |
 ABT-751 |
|||
| E1KS1165 | EnoGene | 10mg | EUR 521 |
 ABT-492 |
|||
| E1KS1553 | EnoGene | 5mg | EUR 1111 |
ABT-737 |
|||
| A8193-10 | ApexBio | 10 mg | EUR 154 |
|
Description: ABT-737 is a novel and potent inhibitor of B-cell lymphoma 2 (BCL-2) family proteins, which are critical for cell survival and overexpressed in many tumor cells, with high affinity towards BCL-XL, BCL-2, and BCL-w but no affinity towards less homologous proteins, such as BCL-B, MCL-1, and A1. |
|||
ABT-737 |
|||
| A8193-100 | ApexBio | 100 mg | EUR 606 |
|
Description: ABT-737 is a novel and potent inhibitor of B-cell lymphoma 2 (BCL-2) family proteins, which are critical for cell survival and overexpressed in many tumor cells, with high affinity towards BCL-XL, BCL-2, and BCL-w but no affinity towards less homologous proteins, such as BCL-B, MCL-1, and A1. |
|||
ABT-737 |
|||
| A8193-5 | ApexBio | 5 mg | EUR 108 |
|
Description: ABT-737 is a novel and potent inhibitor of B-cell lymphoma 2 (BCL-2) family proteins, which are critical for cell survival and overexpressed in many tumor cells, with high affinity towards BCL-XL, BCL-2, and BCL-w but no affinity towards less homologous proteins, such as BCL-B, MCL-1, and A1. |
|||
ABT-737 |
|||
| A8193-5.1 | ApexBio | 10 mM (in 1mL DMSO) | EUR 148 |
|
Description: ABT-737 is a novel and potent inhibitor of B-cell lymphoma 2 (BCL-2) family proteins, which are critical for cell survival and overexpressed in many tumor cells, with high affinity towards BCL-XL, BCL-2, and BCL-w but no affinity towards less homologous proteins, such as BCL-B, MCL-1, and A1. |
|||
ABT-737 |
|||
| A8193-50 | ApexBio | 50 mg | EUR 398 |
|
Description: ABT-737 is a novel and potent inhibitor of B-cell lymphoma 2 (BCL-2) family proteins, which are critical for cell survival and overexpressed in many tumor cells, with high affinity towards BCL-XL, BCL-2, and BCL-w but no affinity towards less homologous proteins, such as BCL-B, MCL-1, and A1. |
|||
ABT-737 |
|||
| A8193-500 | ApexBio | 500 mg | EUR 1558 |
|
Description: ABT-737 is a novel and potent inhibitor of B-cell lymphoma 2 (BCL-2) family proteins, which are critical for cell survival and overexpressed in many tumor cells, with high affinity towards BCL-XL, BCL-2, and BCL-w but no affinity towards less homologous proteins, such as BCL-B, MCL-1, and A1. |
|||
ABT-737 |
|||
| A8193-S | ApexBio | Evaluation Sample | EUR 81 |
|
Description: ABT-737 is a novel and potent inhibitor of B-cell lymphoma 2 (BCL-2) family proteins, which are critical for cell survival and overexpressed in many tumor cells, with high affinity towards BCL-XL, BCL-2, and BCL-w but no affinity towards less homologous proteins, such as BCL-B, MCL-1, and A1. |
|||
 ABT-199 |
|||
| A8194-1 | ApexBio | 1 mg | EUR 131 |
|
Description: ABT-199, developed through a structure-based reverse engineering process, is a novel and specific inhibitor of B-cell lymphoma/leukemia 2 (BCL-2) maintaining a sub-nanomolar affinity towards BCL-2 and over three orders of magnitude less affinity towards BCL-XL |
|||
ABT-199 |
|||
| A8194-5 | ApexBio | 5 mg | EUR 270 |
|
Description: ABT-199, developed through a structure-based reverse engineering process, is a novel and specific inhibitor of B-cell lymphoma/leukemia 2 (BCL-2) maintaining a sub-nanomolar affinity towards BCL-2 and over three orders of magnitude less affinity towards BCL-XL |
|||
ABT-199 |
|||
| A8194-5.1 | ApexBio | 10 mM (in 1mL DMSO) | EUR 421 |
|
Description: ABT-199, developed through a structure-based reverse engineering process, is a novel and specific inhibitor of B-cell lymphoma/leukemia 2 (BCL-2) maintaining a sub-nanomolar affinity towards BCL-2 and over three orders of magnitude less affinity towards BCL-XL |
|||
ABT-199 |
|||
| A8194-50 | ApexBio | 50 mg | EUR 838 |
|
Description: ABT-199, developed through a structure-based reverse engineering process, is a novel and specific inhibitor of B-cell lymphoma/leukemia 2 (BCL-2) maintaining a sub-nanomolar affinity towards BCL-2 and over three orders of magnitude less affinity towards BCL-XL |
|||
ABT-199 |
|||
| A8194-500 | ApexBio | 500 mg | EUR 1442 |
|
Description: ABT-199, developed through a structure-based reverse engineering process, is a novel and specific inhibitor of B-cell lymphoma/leukemia 2 (BCL-2) maintaining a sub-nanomolar affinity towards BCL-2 and over three orders of magnitude less affinity towards BCL-XL |
|||
ABT-199 |
|||
| A8194-S | ApexBio | Evaluation Sample | EUR 81 |
|
Description: ABT-199, developed through a structure-based reverse engineering process, is a novel and specific inhibitor of B-cell lymphoma/leukemia 2 (BCL-2) maintaining a sub-nanomolar affinity towards BCL-2 and over three orders of magnitude less affinity towards BCL-XL |
|||
 ABT-239 |
|||
| HY-12195 | MedChemExpress | 10mg | EUR 337 |
ABT-751 |
|||
| HY-13270 | MedChemExpress | 50mg | EUR 394 |
 ABT-046 |
|||
| HY-15197 | MedChemExpress | 10mM/1mL | EUR 420 |
 ABT-670 |
|||
| HY-19483 | MedChemExpress | 1mg | EUR 849 |
 ABT-639 |
|||
| HY-19721 | MedChemExpress | 100mg | EUR 2943 |
ABT-737 |
|||
| HY-50907 | MedChemExpress | 10mM/1mL | EUR 155 |
 ABT-072 |
|||
| HY-101634 | MedChemExpress | 10mg | EUR 1399 |
 Sulfo-Cyanine 3 NHS ester |
|||
| 263 | AAT Bioquest | 10 mg | EUR 480 |
|
|||
) Zotarolimus(ABT-578) |
|||
| B4786-25 | ApexBio | 25 mg | EUR 741 |
|
Description: Zotarolimus(ABT-578) is an anti-proliferative drug used exclusively in coronary drug eluting stent [1]. Zotarolimus(ABT-578) is an analogue of rapamycin and an anti-proliferative drug. |
|||
Zotarolimus(ABT-578) |
|||
| B4786-5 | ApexBio | 5 mg | EUR 347 |
|
Description: Zotarolimus(ABT-578) is an anti-proliferative drug used exclusively in coronary drug eluting stent [1]. Zotarolimus(ABT-578) is an analogue of rapamycin and an anti-proliferative drug. |
|||
 ABT 702 dihydrochloride |
|||
| B5298-10 | ApexBio | 10 mg | EUR 412 |
|
Description: IC50: 1.7 nM for adenosine kinaseAdenosine (ADO) is an endogenous homeostatic inhibitory neuromodulator that reduces cellular excitability at sites of tissue injury and inflammation. |
|||
ABT 702 dihydrochloride |
|||
| B5298-100 | ApexBio | 100 mg | EUR 1708 |
|
Description: IC50: 1.7 nM for adenosine kinaseAdenosine (ADO) is an endogenous homeostatic inhibitory neuromodulator that reduces cellular excitability at sites of tissue injury and inflammation. |
|||
ABT 702 dihydrochloride |
|||
| B5298-5 | ApexBio | 5 mg | EUR 276 |
|
Description: IC50: 1.7 nM for adenosine kinaseAdenosine (ADO) is an endogenous homeostatic inhibitory neuromodulator that reduces cellular excitability at sites of tissue injury and inflammation. |
|||
ABT 702 dihydrochloride |
|||
| B5298-5.1 | ApexBio | 10 mM (in 1mL DMSO) | EUR 316 |
|
Description: IC50: 1.7 nM for adenosine kinaseAdenosine (ADO) is an endogenous homeostatic inhibitory neuromodulator that reduces cellular excitability at sites of tissue injury and inflammation. |
|||
ABT 702 dihydrochloride |
|||
| B5298-50 | ApexBio | 50 mg | EUR 1181 |
|
Description: IC50: 1.7 nM for adenosine kinaseAdenosine (ADO) is an endogenous homeostatic inhibitory neuromodulator that reduces cellular excitability at sites of tissue injury and inflammation. |
|||
) Paritaprevir(ABT-450) |
|||
| 20-abx184297 | Abbexa |
|
|
|
|||
) Linifanib (ABT-869) |
|||
| E1KS1003 | EnoGene | 5mg | EUR 521 |
) ABT-888 (Veliparib) |
|||
| E1KS1004 | EnoGene | 5mg | EUR 325 |
) Lopinavir(ABT-378) |
|||
| E1KS1380 | EnoGene | 10mg | EUR 403 |
 ABT 724 trihydrochloride |
|||
| B6981-10 | ApexBio | 10 mg | EUR 308 |
|
Description: ABT 724 trihydrochloride is a highly selective D4 dopamine agonist [1][2], with an EC50 of 281 nM in increasing the binding activity of GTP?S in CHO cells transfected with human D4 receptors, and of 12.4 nM in increasing Ca2+ influx of HEK-293 cells co-transfected with a G protein (G?q05). |
|||
ABT 724 trihydrochloride |
|||
| B6981-50 | ApexBio | 50 mg | EUR 1136 |
|
Description: ABT 724 trihydrochloride is a highly selective D4 dopamine agonist [1][2], with an EC50 of 281 nM in increasing the binding activity of GTP?S in CHO cells transfected with human D4 receptors, and of 12.4 nM in increasing Ca2+ influx of HEK-293 cells co-transfected with a G protein (G?q05). |
|||
Linifanib (ABT-869) |
|||
| A2949-100 | ApexBio | 100 mg | EUR 780 |
|
Description: Linifanib (ABT-869) is an effective ATP-competitive tyrosine kinase inhibitor against the platelet-derived growth factor (PDGF) receptor and the vascular endothelial growth factor receptor (VEGFR) families, including constitutively active FMS-like receptor tyrosine kinase 3 (FLT3) [1][2]. |
|||